CNS Pharmaceuticals Inc. CNSP Archives - Page 19 of 22

ThursdayJan 07, 2021 9:45 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at the H.C. Wainwright BioConnect 2021 Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its CEO, John Climaco, will present at the virtual H.C. Wainwright BioConnect 2021 Conference. The event is slated to be held from Jan. 11-14, 2021, with Climaco’s presentation scheduled for 6:00 a.m. ET on the first day of the event. Interested parties should visit https://ibn.fm/09lxu to register. The webcast will be available on demand starting at 6:00 a.m. ET on Monday, Jan. 11, 2021. Replays of the presentation will be available…

MondayJan 04, 2021 2:06 pm

CNS Pharmaceuticals (NASDAQ: CNSP) Conducts Public Offering Funding Effort, Appears in Syndicated Broadcast on Brain Cancer Drug Advances

Neuro-oncology drug developer CNS Pharmaceuticals is completing an underwritten public offering of common stock shares and warrants in a bid to fund its upcoming Phase 2 trials for a candidate in fighting glioblastoma brain cancers CNS’s Phase 2 trials are scheduled to begin during Q1 of 2021, building on a Phase 1 trial in which 44 percent of patients saw improvement and one patient has survived cancer-free for nearly 15 years The company has designed an ambitious, adaptive trial that allows for an interim analysis of data and adjustments for efficiency in bringing the drug candidate, Berubicin, to hoped-for approval…

TuesdayDec 29, 2020 11:42 am

Hour of Truth Approaching in CNS Pharmaceuticals (NASDAQ: CNSP) Testing of Drug Candidate Against Deadly Brain Cancer

A novel anthracycline believed to be effective in combatting deadly glioblastoma brain cancers by crossing the blood-brain barrier and zeroing in on the tumor will begin Phase 2 trials during Q1 of next year The drug, Berubicin, is being developed by CNS Pharmaceuticals after initial testing nearly 15 years ago resulted in improvements among some subjects, including one who has survived cancer-free since that time The company, in collaboration with Polish sub-licensee partner WPD Pharmaceuticals, plans a multinational staged series of trials that will attempt to keep time and costs to outcome at a minimum As part of the effort,…

MondayDec 28, 2020 11:09 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Featured in Syndicated Broadcast

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it was featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers CNS Pharmaceuticals’ Investigational New Drug (“IND”) application for its lead product candidate, Berubicin, for the treatment of Glioblastoma Multiforme (“GBM”). The IND is now approved and in effect as filed with the U.S. Food and Drug…

WednesdayDec 23, 2020 9:00 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Pricing of $10M Public Offering

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock and warrants to purchase up to 2,500,000 shares of common stock. According to the update, the shares of common stock and warrants are being sold together at a combined public offering price of $2.00 per share and warrant. The warrants will have an exercise price of $2.20 per share and will be immediately exercisable and expire five years from…

TuesdayDec 22, 2020 12:07 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moving Forward with Clinical Trials in 2021 after Receiving FDA Approval for IND for Berubicin

The company is scheduled to conduct three clinical trials in 2021 for Berubicin – two Phase II and the first-ever Phase I in pediatric patients FDA modified the trial design to designate overall survival as the trial’s primary endpoint The market for brain tumor therapies is expected to grow at a CAGR of 10% and reach an estimated $1.6 billion in 2025 CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announced that it obtained the Food and Drug Administration’s Investigational New Drug…

FridayDec 18, 2020 8:30 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Hosts Conference Call to Discuss IND Approval, Phase 2 Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, on Thursday announced that it will be holding a conference call to discuss its recently approved Investigational New Drug (“IND”) application involving its lead product candidate Berubicin for the treatment of Glioblastoma Multiforme (“GBM”). The company also intends to discuss its planned Phase 2 Berubicin clinical trial on the call slated for Friday, December 18, 2020 at 8:30 AM ET. Interested parties may access the call by dialing (800) 226-2188 (domestic) or (602) 563-8462 (international)…

ThursdayDec 17, 2020 9:17 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures FDA Approval of IND Application for Brain Cancer Drug Candidate Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, this morning announced that it has received US Food and Drug Administration (“FDA”) approval of its Investigational New Drug (“IND”) application on its lead product candidate Berubicin for the treatment of Glioblastoma Multiforme (“GBM”). This approval signifies a crucial step for the company in launching a potentially pivotal trial to investigate the efficacy of Berubicin in adults with GBM who have been unsuccessful with first-line therapy. In addition, following recent correspondence with the FDA, the…

WednesdayDec 16, 2020 12:17 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Appears on ‘Want Money Got Money’ Podcast

CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent “Want Money Got Money” podcast. Hosted by author, founder, speaker and CEO Sam Kamani, the podcast series shares stories, secrets and skills of the world’s most brilliant and interesting start-up founders and investors. During the podcast, Climaco talked about recent research conducted by CNSP founder Dr. Waldemar Priebe that studies the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. In addition, Climaco discussed CNS Pharmaceuticals’ lead drug candidate, Berubicin. The drug is being proposed as a treatment for GBM. A Phase I clinical…

ThursdayDec 10, 2020 12:43 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Brain Cancer Drug IND Filing Accepted for Review by FDA

CNS Pharmaceuticals featured in audio broadcast distributed to thousands of syndication points. Berubicin IND accepted for review by FDA Phase 1 trial showed 44% of patients experiencing clinical benefit of stable disease or better Adult Phase 2 trials to commence in Q1 2021 The IND filing for brain cancer drug Berubicin has been accepted for review by the U.S. Food and Drug Administration (“FDA”), reports CNS Pharmaceuticals (NASDAQ: CNSP), the company now responsible for the drugs’ development. That news was featured in a recent syndicated NetworkNewsAudio (“NNA”) broadcast, which covered CNS Pharmaceuticals’ recent submission of an Investigational New Drug (“IND”)…

Site Search

Company Search

Tag: CNS Pharmaceuticals Inc. CNSP